CAS
BDTX icon

CTC Alternative Strategies’s Black Diamond Therapeutics BDTX Stock Holding History

CTC Alternative Strategies’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,000
Closed -$55.8K – 194
2024
Q1 		$55.8K Buy
+11,000
New +$44.4K 0.03% 109

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CTC Alternative Strategies's BDTX Position: Q2 2024 in Review

CTC Alternative Strategies sold out of Black Diamond Therapeutics (BDTX) in Q2 2024, closing a stake of 11,000 shares — an estimated $55.8K sold.

CTC Alternative Strategies first reported a position in BDTX in Q1 2024 and held it in 1 quarter. The position peaked at $55.8K in Q1 2024. 90 funds tracked by Wall St. Rank hold BDTX as of Q2 2024.

  • CTC Alternative Strategies reported no remaining Black Diamond Therapeutics position as of Q2 2024 after selling out during the quarter.
  • CTC Alternative Strategies sold 11,000 Black Diamond Therapeutics shares in Q2 2024, an estimated $55.8K.
  • CTC Alternative Strategies first reported a position in Black Diamond Therapeutics in Q1 2024 and held it in 1 quarter.
  • CTC Alternative Strategies's Black Diamond Therapeutics position peaked at $55.8K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2024.

Based on CTC Alternative Strategies's 13F filing for Q2 2024, filed 2 Aug 2024.